Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant

Part of paid clinical trials in Dallas, Texas.

Sponsor
Methodist Health System
Study ID
NCT05224583
Status
Enrolling By Invitation

Conditions

  • BK Viremia
  • Kidney Transplant Infection
  • Liver Transplant Infection
  • Polyomavirus Infections

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Simultaneous Liver-Kidney Transplant — PROCEDURE
    Simultaneous Liver-Kidney Transplant

Study Details

The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.

Key Dates

Start date
Nov 17, 2021
Status verified
Jan 2026
Primary completion
Nov 17, 2027
Completion
Nov 17, 2028

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Simultaneous Liver-Kidney Transplant patients population at MDMC
    Consecutive SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).

Primary Outcome Measure

To characterize the prevalence of BKV in the SLK patient population at (Methodist Dallas Medical Center)MDMC. [ Time Frame: over a 6-year period (2015 to 2020). ]

Locations (1)

FacilityCityStateZIPSite coordinators
Methodist Dallas Medical CenterDallasTexas75203-

Find similar trials in Dallas, TX

By research site
Methodist Dallas Medical Center· Dallas, TX

Related Studies